Europreneurs MediaBusiness · Startups · The future of Europe
Startups · United Kingdom

Boltz raises USD 110m Series A for AI molecular design

Bessemer Venture Partners led the round less than a year after Boltz launched with USD 28m. The company says six of the world's 20 largest drug makers already use its models and usage has grown 50 fold since June.

Boltz announcement graphic with the words AI that designs the molecules of tomorrow next to a green rendering of a protein surface
Image: Boltz (company graphic, Boltz Series A announcement). Graphic published with the funding announcement; not a photograph.

Boltz, a London based company building AI models for designing small molecules and proteins, has raised USD 110 million in a Series A round led by Bessemer Venture Partners, it announced on 18 November. All existing investors took part, including Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures.

New investors include Greycroft, F-Prime Capital, Hummingbird and Benchling. Bessemer's Andrew Hedin and Byron Deeter will work with the company, according to the announcement. Boltz did not disclose a valuation.

From open source project to company

The founders, chief executive Gabriele Corso, chief technology officer Jeremy Wohlwend and head of research Saro Passaro, were among the core developers of open source molecular models that came out of Professor Regina Barzilay's lab at MIT, Bessemer said. Bessemer says those models match the performance of closed systems such as AlphaFold3. They have more than 5 million downloads and are used by more than 100,000 scientists, according to the investor.

Boltz came out of stealth less than a year ago with USD 28 million, Endpoints News reported. Andreessen Horowitz, which co-led that seed round, said its pharma partners kept telling it they were all using the same open source models from MIT. The company has since grown to a team of 40 scientists and engineers.

What the company sells

Boltz launched Boltz Lab in January, a platform that lets scientists or AI agents use its latest models without building their own infrastructure. In June it released its first proprietary models: BoltzMol-1 for small molecule design and BoltzProt-1 for protein design. The company says it found small molecule hits and designed protein binders for a majority of the difficult targets it pursued, at a fraction of the time and cost of traditional methods.

Six of the world's 20 largest pharmaceutical companies now use the platform, Boltz said, naming Pfizer, GSK, Takeda and BMS. Bessemer added that ingredients group DSM Firmenich is also a customer. Since June, the volume of molecular tokens processed for users has grown 50 fold, according to the company.

A usage based model

Unlike AI drug discovery companies that build their own pipelines of medicines or sign large target by target partnerships, Boltz charges for model usage, measured in what it calls molecular tokens. Customers keep ownership of the molecules they design. Boltz can also train exclusive versions of its models on a partner's own data, a16z said. Its tools can be called through an API and from coding agents such as Claude Code and Codex.

"Models this powerful should be accessible to every scientist, rather than confined to a single company's proprietary pipeline or locked behind complex, restrictive strategic partnerships," the Boltz team wrote.

The new money will go into compute, data and hiring, the company said, with the long term goal of letting a scientist move from a therapeutic idea to a molecule ready for human testing without leaving the computer.

What it means for founders and investors

The round comes a day after Isomorphic Labs raised USD 5 billion, and together the two deals show how much capital London based AI drug design companies can now attract. The business models differ sharply, though. Isomorphic builds its own drug programmes, while Boltz is betting on becoming infrastructure that every lab pays to use, closer to a software company than a biotech.

For founders, Boltz is a clear example of open source as a go to market strategy: wide adoption of free models meant that every partnership Boltz has signed so far began as inbound interest from scientists, according to Bessemer. For investors in European biotech, a cheap and widely available design layer could lower the cost of early discovery for startups such as Allox, while raising the bar for companies whose main asset is a proprietary model. The round was led by a US firm and most of the named backers are US investors, which also shows that European AI bio companies still tend to raise their larger rounds across the Atlantic.

Spotted an error? Email contact@europreneursmedia.com and we'll correct it. See our corrections policy and editorial standards.

Keep reading

All news →
Europe

BASF ends its pursuit of Evonik after two rejected offers

Germany's largest chemicals group said Evonik's board had not engaged meaningfully and that a higher price could not be justified. The decision ends a two month standoff over a combination of Germany's two largest chemicals groups.

·BASF (news release, 19 Nov 2026)